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1. Introduction
Paralleling  the  burgeoning  epidemics  of  childhood obesity,  nonalcoholic  fatty  liver  dis‐
ease (NAFLD) is  now recognized as the most common cause of chronic liver disease in
children [1,2].
NAFLD is a clinic-pathological condition defined by the accumulation of intrahepatic trigly‐
ceride fat (IHTF) content in the absence of alcohol consumption [1,2].
NAFLD encompasses a wide spectrum of liver damage, ranging from asymptomatic steato‐
sis with elevated or normal aminotransferases to steatosis with inflammation, ballooning de‐
generation and pericellular fibrosis (Nonalcoholic Steatohepatitis, NASH) to cirrhosis [2,3].
Although there are limited long-term data on the natural history of NAFLD in children,
NASH is increasingly diagnosed in obese children [4] and it may progress to cirrhosis even
in this age group [2,5]. In addition, children with NAFLD have a 13.6-fold higher risk of
mortality or requiring a liver transplant as compared to age/sex matched controls [6].
During the last years there has been a growing interest in the relationship between NAFLD
and the development of metabolic and cardiovascular diseases [7-9].
Several  lines  of  evidence  have  shown  that  in  obese  children  and  adolescents  excessive
accumulation of IHTF is associated with important alterations in glucose, fatty acid (FA),
lipoprotein metabolism and inflammation,  suggesting that IHTF represents a strong risk
factor for the development of the Metabolic Syndrome (MetS) and type 2 diabetes melli‐
tus (T2D) [7-10].
© 2013 D’Adamo et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Although a multifactorial pathogenesis of NAFLD has been postulated [12-14], obesity and
insulin resistance represent two important players in the development of the early stages of
the disease [2,14]. Interestingly, although the insulin resistance state could explain the rela‐
tionship between NAFLD and the development of metabolic alterations [10,15], the presence
of liver steatosis is also an important marker of multiorgan insulin resistance [16], opening a
debate as to whether hepatic steatosis is a consequence or cause of insulin resistance.
Therefore, it would be of paramount importance to identify children affected by NAFLD
and to better understand the pathogenesis of this condition in order to prevent the develop‐
ment of the associated metabolic complications early in life.
2. Definition and prevalence of NAFLD
Despite fatty liver is becoming one of the most common hepatic alterations in obese children
[1,2], the prevalence of pediatric NAFLD is uncertain, mainly due to the methods used to
assess fatty liver.
NAFLD is defined as an IHTF content > 5% of liver volume or weight and as a presence
≥5% of  hepatocytes  containing  intracellular  triglycerides,  in  the  absence  of  alcohol  con‐
sumption [17,18].
The gold standard for diagnosing NAFLD is liver biopsy [19,20]. Liver biopsy allows an ac‐
curate assessment of histopatological findings, providing information on the type of NAFLD
(simple steatosis or steatohepatitis) and the various degrees of hepatic fibrosis [20]. Howev‐
er, the main limitation of the application of liver biopsy in the pediatric age group is due to
the fact that it is an invasive procedure; thus, it is not considered as first line to screen the
presence of liver disease [19,20].
Although non-invasive methods, such as computer tomography, MRI, or ultrasonography
are unable to distinguish between NASH and other forms of NAFLD [19,21], they have an
acceptable sensitivity and specificity for the diagnosis of increased fat accumulation in the
liver [21]. Furthermore, ultrasound has been shown to have a good correlation with the his‐
tological findings of liver biopsy, particularly macrovescicular steatosis [22].
In clinical practice, combining liver function tests, such as serum aminotransferases [18],
with liver ultrasound represents a useful way of identifying the presence of liver steatosis in
obese children.
In spite of the method used, it is clear that the prevalence of NAFDL is increasing in chil‐
dren and adolescence. NAFLD affects 2.6% of normal children [23] and up to 77% of obese
individuals [24,25]. Pediatric NAFLD extends beyond North America according to centers in
Europe, Asia, South America and Australia [2,3]. The prevalence of fatty liver in obese chil‐
dren in China, Italy, Japan, and the United States has been reported to be between 10% and
77% [2,3]. Data derived from the National Health and Nutrition Examination Survey III
(1988-1994) suggest that approximately 3% of adolescents present abnormal serum amino‐
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transferase values [26]. Moreover, studies from autopsies of 742 children (ages 2–19 years)
reported fatty liver prevalence at 9.6%, and in obese children this rate increased to an alarm‐
ing 38% [25].
NAFLD has been also described in obese prepubertal children. In the study by Manco et al.
[27] NAFLD was detected in children as young as 3 years old.
The prevalence of NAFLD is around 30% in children with a Tanner pubertal stage I, signifi‐
cantly lower when compared to that found in the pubertal age [28].
Alarming data come from our study population of prepubertal Caucasian obese children
[29]. Out of 100 severely obese prepubertal children, liver steatosis was found in 52% and
was equally distributed between the two sexes [29].
Thus, NAFLD in an emerging health problem even in very young age groups.
3. Pathogenesis and risk factors of NAFLD
Although the pathogenetic mechanism of NAFLD is not completely understood, in accord‐
ance with the “two hit hypothesis”, insulin resistance and oxidative stress represent two key
factors for the development and progression of NAFLD/NASH [12,17,20].
3.1. Insulin resistance and central obesity
The “two-hit” model proposes that fat accumulation in the hepatocytes is a prerequisite for
a second hit that induces fibrosis and inflammation [30].
Fat accumulation in the liver is likely to result from insulin resistance and concomitant im‐
pairment of fatty acid (FA) metabolism within liver, skeletal muscle and adipose tissue [31].
Insulin resistance seems to be responsible for abnormalities in lipid storage and lipolysis in
insulin-sensitive tissues, leading to an increased fatty acids flux from adipose tissue to the
liver and subsequent accumulation of triglycerides in the hepatocytes [31]. In particular,
steatosis develops when the rate of FA input (uptake and synthesis with subsequent esterifi‐
cation to triglycerides (TG)) is greater than the rate of FA output (oxidation and secretion)
[11]. The amount of TG in the hepatocytes represents a complex interaction among [11,31]:
hepatic FA uptake, derived from plasma free fatty acid (FFA) released from hydrolysis of
adipose tissue and FFA released from hydrolysis of circulating TG; de novo FA synthesis
(de novo lipogenesis [DNL]); fatty acid oxidation (FAO); FA export within very low-density
lipoprotein (VLDL)-TG.
Obesity is the most important cause in the development of insulin resistance and it has been
demonstrated that the critical determinant of insulin sensitivity is not the degree of obesity
per se but the distribution of fat partitioning [32,33].
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Several studies [32,33] have demonstrated that obese adolescents presenting increased intra‐
myocellular lipid content (IMCL) [32] and visceral fat and decreased subcutaneous fat depo‐
sition are more likely to develop insulin resistance.
There is extensive evidence indicating that central obesity is associated with an impaired in‐
sulin action in obese pediatric populations. Although controversy remains regarding the
contribution of visceral and subcutaneous fat to the development of insulin resistance [33], a
previous study by Cruz et al. [35] showed a direct impact of visceral fat accumulation on
insulin sensitivity and secretion, independently of total body adiposity, in obese children
with a family history of T2D. Indeed, by stratifying a multiethnic cohort of obese adoles‐
cents into tertiles based on the proportion of visceral fat in the abdomen (visceral/subcutane‐
ous fat ratio), insulin resistance (homeostasis model assessment) significantly increased and
insulin sensitivity (Matsuda index) decreased in obese adolescents with high proportion of
visceral fat and relatively low abdominal subcutaneous fat [33].
These findings suggest that obese children and adolescents at risk for developing metabolic
complications are not necessarily the most severely obese, but are characterized by an un‐
favorable lipid partitioning profile.
3.2. Insulin resistance and fatty liver disease: Which comes first?
Despite the demonstrated relationship between IMCL, visceral fat and metabolic dysfunc‐
tion, the ectopic fat deposition in the liver is emerging as the most important marker of insu‐
lin resistance in adults [15] as well as in obese pediatric population [36].
In healthy nondiabetic humans the correlation between the IHTF content and peripheral in‐
sulin resistance was much stronger than the correlation with intramyocellular lipid content,
visceral fat content or subcutaneous fat content [37]. The relationship between liver steatosis
and insulin resistance has been clearly demonstrated in children [36,29]. In our cross section‐
al study, we evaluated insulin resistance indexes between obese prepubertal children with
and without liver steatosis; furthermore insulin resistance indexes were compared to values
of normal weight children. Our results showed that children with NAFLD not only present‐
ed severe obesity but also an increased degree of insulin resistance when compared to the
sex- and age-matched normal weight children [29].
The relationship between insulin resistance and fatty liver disease is not only related to the
presence of liver steatosis, but also to the degree of fatty liver. In a multiethnic cohort of
obese adolescents, Calì et al. [36] clearly showed a significant decrease in insulin sensitivity
and an imbalance between anti- and pro-inflammatory markers [adiponectin and interleu‐
kin 6 (IL-6)] paralleling the severity of hepatic steatosis [36]. In particular, adiponectin, the
most abundant secretory protein produced by adipose tissue, is closely related with insulin
action. Plasma adiponectin concentrations are inversely associated with hepatic steatosis
and metabolic complications [37,38].
Although these findings support the central role of insulin resistance in the development of
fatty liver, several studies have demonstrated that the presence of liver steatosis is an impor‐
tant marker of multiorgan insulin resistance, independently of BMI, percent body fat, and
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visceral fat mass [11,15,36]. In particular, NAFLD has been found to be associated with insu‐
lin resistance in liver (impaired suppression of insulin-mediated glucose production) [39,40],
skeletal muscle (reduced insulin stimulated glucose uptake) [40] and adipose tissue (de‐
crease inhibition of lipolysis by insulin) [41] in obese children and adolescents, independent‐
ly of adiposity.
Recently, Caprio et al. [16] reported that obese adolescents with high liver fat content, inde‐
pendent of visceral and IMCL had an impaired insulin action (as assessed by the hyperinsu‐
linemic-euglycemic clamp) in the liver and in the muscle and early defects in β-cell function
[16]. These results suggest that the liver has a central role in the complex phenotype of the
insulin resistance state in obese adolescents with fatty liver.
Although it is clear that there is an important correlation between insulin resistance and
hepatic steatosis, the mechanisms responsible for the interrelationships between fatty liver
disease and insulin resistance are not clearly understood. In fact, it remains unclear whether
hepatic steatosis is a consequence or the primary event leading to hepatic and subsequently
peripheral insulin resistance.
Petersen et al. [42] showed that the lack of adipose tissue in the congenital lipodystrophy is
characterized by extreme insulin resistance associated with massive hepatic fat accumula‐
tion; intervention with subcutaneous leptin administration in these patients improved
whole-body insulin sensitivity mainly due to the mobilization of the excessive fatty liver
content.
Models of patients with liver cirrhosis in which hepatic dysfunction is known to be the pri‐
mary disturbance provide strong support that insulin resistance in peripheral tissues devel‐
ops secondary to liver disease [43]. 60-80% of patients with liver cirrhosis are glucose
intolerant and in 10-15% diabetes occurs relatively rapidly (over a period of 5 years). Diabe‐
tes complicating liver cirrhosis, also known as hepatogenous diabetes, and the common
form of T2D are the results of a marked reduction in insulin action and a β-cell secretion de‐
fect that is not able to compensate the severity of insulin resistance [43,44]. The important
role of peripheral insulin resistance in the glucose tolerance of cirrhosis has been highlighted
by the observation that liver transplantation, when the dosage of immunosuppressive
agents was reduce and corticosteroids withdrawn, was able to restore normal insulin sensi‐
tivity not only in the liver but also at the level of the skeletal muscle and adipose tissue and
normalizes glucose tolerance in most patients with diabetes [43,44].
The mechanism by which IHTF has an important systemic consequence to adversely affect
insulin sensitivity is unknown. However, it has been proposed that fatty liver might inter‐
fere with insulin degradation [45]; the resultant hyperinsulinemia may potentially be able to
impair insulin action in peripheral tissues, as shown in benign insulinoma induced hyperin‐
sulinemia [43,44,46]. This hyperinsulinemia-induced mechanism may be justified also based
on the finding of the reverse experiment: when the prolonged infusion of octreotide was ad‐
ministered to extremely insulin-resistant cirrhotic individuals, the correlation of hyperinsuli‐
nemia was paralleled by the restoration of normal insulin sensitivity [43,47].
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Although these data showed a clear possibility that intrahepatic fat accumulation plays a
key role in the onset of insulin resistance and insulin resistance syndrome, longitudinal data
are needed in order to clarify which abnormality comes first.
3.3. Oxidative stress
In accordance with the “two hit hypothesis”, dysfunction of various oxidation pathways
within the hepatocytes and subsequent overproduction of reactive oxygen species (ROS),
may result in the peroxidation of accumulated lipids, inflammation, hepatocellular apopto‐
sis and fibrogenesis [31].
Obese subjects affected by NAFLD present an impaired oxidant-antioxidant status than sub‐
jects without [12,48].
Interestingly, we recently observed [48] that obese prepubertal children affected by liver
steatosis had impaired levels of receptors for advanced glycation endproducts (RAGEs),
which has been demonstrated to be correlated with the progression of several metabolic and
cardiovascular diseases. In particular, obese prepubertal children with liver steatosis pre‐
sented decreased RAGEs levels compared with children without liver disease, underling
that oxidative stress could play a role even in the early stages of the disease [48].
3.4. Genetic and environmental factors associated with fatty liver disease
Several genetic and environmental factors are likely responsible for NAFLD and its progres‐
sion from simple steatosis to NASH.
In fact, although the development of NAFLD is strongly linked to obesity and insulin resist‐
ance, there are obese individuals who do not have NAFLD, and since NAFLD can occur in
normal-weight individuals with normal metabolic profile, thus multiple genetic and envi‐
ronmental factors should be involved in its development [49].
Initial evidence for a genetic component of NAFLD comes from ethnic variation in NAFLD
prevalence [50]. Children from certain ethnicities are predisposed to NAFLD, primarily His‐
panics, Asians and Native Americans [25,50].
Furthermore, a familial aggregation study of fatty liver in overweight children with and
without NAFLD found that fatty liver is a highly heritable trait. Family members of children
with biopsy-proven NAFLD and overweight children without NAFLD were evaluated by
magnetic resonance imaging (MRI). Fatty liver was identified in 17% of siblings and 37% of
parents of overweight children without NAFLD and in 59% of siblings and 78% of parents
of children with NAFLD [51].
Interestingly, Romeo et al. [52] conducted the first genome-wide association scan conducted
in a large multiethnic population. The authors demonstrated that the patatin-like phospholi‐
pase domain containing protein 3 (also known as adiponutrin) gene was strongly associated
with IHTF content in adults [52].
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These findings have been recently supported by Santoro et al. [53]. By genotyping the
PNLPA3 SNP in a multiethnic group of 85 obese youths, the authors found that the PNPLA3
rs738409 SNP gene confers susceptibility to hepatic steatosis.
Nutrition and physical activity are important environmental factors that determine risk in
NAFLD.
Excess food intake and lack of exercise contribute to weight gain, which has been shown to
contribute to the progression of liver fibrosis in patients with NAFLD [54]. Specific dietary
factors may also play either protective or antagonistic roles in the development and progres‐
sion of NAFLD. An increased consumption of meat and soft drinks and low consumption of
fish were found to be associated with NAFLD cases compared with controls [49]. Further‐
more, low intakes of polyunsaturated fatty acid (PUFA) and high intakes of saturated fat
and cholesterol were also shown to be associated with NAFLD [49]. Other studies have
shown higher-carbohydrate and lower-fat diets to be associated with more progressive dis‐
ease [49,55]. Notably, very recent animal data have shown that in both mice [49,56] and non-
human primates [49] exposure to a maternal high-fat diet leads to a disturbing development
and progression of NAFLD in the offspring.
It has been proposed that increase consumption of fructose in soft drinks and fruit drinks
may have a role in the pathogenesis of NAFLD [2]. In one study, children with biopsy-pro‐
ven NAFLD were shown to have significantly elevated plasma TG levels and oxidative
stress levels after consumption of fructose as compared with glucose [57]. However, chil‐
dren without NAFLD were found to have no differences in TG or oxidative stress levels fol‐
lowing the consumption of glucose compared with fructose [2].
Small  intestinal  bacterial  overgrowth  may  be  an  additional  environmental  factor  in‐
volved in NAFLD pathogenesis,  and dietary supplements such as probiotics could have
a  beneficial  effect  [49].  Evidences  from animal  studies  have  shown that  small  intestinal
bacterial  overgrowth increases  gut  permeability  leading to  portal  endotoxaemia  and in‐
creased  circulating  inflammatory  cytokines,  both  of  which  have  been  implicated  in  the
progression of NAFLD [58,59].
4. NAFLD, metabolic and cardiovascular complications in obese children
and adolescents
4.1. NAFLD and metabolic complications
NAFLD is nowadays considered the hepatic manifestation of the MetS in adults as well as in
children [60]. This is not surprising since NAFLD is closely associated with obesity, insulin
resistance, and alterations in glucose and lipid metabolism [44].
The association between NAFLD and MetS has been clearly demonstrated by Burgert et al.
[61,62]. In 392 obese adolescents, elevated alanine aminotransferases (ALT) (>35 U/L) levels
were found in 14% of participants, with a predominance of White/Hispanic. After adjusting
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for potential confounders, rising ALT levels were associated with deterioration in insulin
sensitivity and glucose tolerance, as well as increasing FFA and TG levels. Furthermore, in‐
creased hepatic fat accumulation was found in 32% of obese adolescents and was associated
with decreased insulin sensitivity and increased lipid levels and visceral fat [61]. These re‐
sults demonstrate that in obese children and adolescents, hepatic fat accumulation is associ‐
ated with insulin resistance, dyslipidemia and altered glucose metabolism.
In addition, the Korean National Health and Nutrition Examination Survey found partici‐
pants aged 10 – 19 years with three or more risk factors for MetS had an odds ratio that of
6.2 (95 % CI 2.3 – 16.8) for an elevated serum ALT, which they used as an indicator of fatty
liver [62]. Furthermore, a case – control study of overweight children with biopsy-proven
NAFLD and age-, sex-, and obesity-matched controls found that children with NAFLD were
significantly more likely to have MetS than obese controls without evidence of fatty liver
disease [9].
More recently, in a large histology-based study conducted in children with NAFLD [63],
MetS was diagnosed in 25.6 % of the subjects, with central obesity and hypertension being
the most common of the MetS features observed. In addition, a diagnosis of MetS was pre‐
dictive of steatosis severity, NASH, hepatocellular ballooning and NAFLD pattern [63].
In a recent study by our group [64], we assessed the role of liver steatosis in defining MetS
in prepubertal children. The prevalence of the MetS was around 14% and increased to 20%
when liver steatosis was included as an additional diagnostic criterion. These findings un‐
derline not only the relevance of the MetS even among prepubertal children but also empha‐
size the potential importance of testing for fatty liver as a component of the MetS already in
this age group [64] (figure 1).
Figure 1. Prevalence of components of the MetS among obese prepubertal children [64].(TG, triglycerides; HDL-C,
high density lipoprotein cholesterol; IGT, impaired glucose tolerance; NAFLD, non alcoholic fatty liver disease)
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NAFLD in youth may be considered not only a strong risk factor for MetS, but also for T2D
[36]. In a cohort of 118 obese adolescents [36] stratifyied according to tertiles of hepatic fat
content (as assessed by fat gradient MRI), independently of obesity, the severity of fatty liv‐
er was associated with the presence of prediabetes [impaired glucose tolerance (IGT) and
impaired fasting glucose (IFG)/IGT]. In fact, paralleling the severity of hepatic steatosis,
there was a significant decrease in insulin sensitivity and impairment in β-cell function, as
indicated by the fall in the disposition index (DI). Furthermore, paralleling the severity of
fatty liver, there was a significant increase in the prevalence of MetS, suggesting that hepatic
steatosis may probably be a predictive factor of MetS in children [36].
The important role of intrahepatic fat content in the development of metabolic complications
in obese subject has been recently underlined by Fabbrini et al. [15]. The authors showed
that in adults with high IHTF insulin action in liver, skeletal muscle and adipose tissue was
impaired and hepatic VLDL-TG secretion rate was increased. In contrast, they were not able
to observe these metabolic alterations in subjects with high visceral fat volume and matched
for IHTF. Therefore, the authors demonstrated that IHTF and not visceral fat is a better
marker of metabolic derangements associated with obesity [15,16].
4.2. NAFLD and cardiovascular disease
Recent evidences suggests that individuals with NAFLD are also at high risk for coronary
heart disease [3,43]. In adults, elevated serum ALT have been associated with increased risk
of cardiovascular and all cause mortality (in addition to liver mortality) [3,65].
A study in Turkish children [66] showed that carotid artery intima-media thickness is signif‐
icantly higher in obese children with fatty liver than in obese children without fatty liver or
normal weight control.
In addition, Pacifico et al. [67] reported that carotid artery intima-media thickness was high‐
est in obese children with echogenic liver and severity of liver fat was an independent pre‐
dictor of intima-media thickness after adjustment for known cardiovascular factors.
However, given the lack of long-term longitudinal cohort studies in pediatric fatty liver dis‐
ease, the relationship between the natural history of the disease and the actual risk for future
cardiac events is unclear.
5. Conclusions
The prevalence of fatty liver disease is increasing in obese children and adolescence.
Although the exact pathogenetic mechanism is still unclear, there is an urgent need to screen
obese children for this pathology. A misdiagnosis of fatty liver could represent a serious risk
factor for the development of its associated metabolic and cardiovascular complications dur‐
ing childhood and for exacerbated metabolic abnormalities later in life.
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